Company intelligence / Profile preview

FL94 Inc.

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Preclinical

Overview

FL94 is an early-stage biotechnology company developing a proprietary platform for "Protein Editing" using small molecules. The company aims to unlock undruggable targets by editing protein structure and function, leveraging novel chemistry modalities and advanced machine learning for generative design. No clinical results have been reported as the company remains in preclinical/platform development stages[1][3][4].

Therapeutic areas: Other
Modalities: Small moleculesNovel chemistry modalities (including protein editing chemistries)
Industry: Biotech

Partnerships

Backed/incubated by Flagship Pioneering; no external pharma/biotech partnerships publicly disclosed as of now[1].

Beyond the preview

Go deeper on FL94 Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FL94 Inc..

Explore the full profile